The growing acceptance of cannabis among older adults has raised critical questions about cognitive safety in a population already vulnerable to age-related decline. This concern becomes particularly acute as baby boomers increasingly turn to cannabis for medical conditions, often without clear guidance on neurological risks.
Analyzing nearly 80,000 UK Biobank participants and 12,222 U.S. veterans with cannabis use disorder, researchers found no evidence that cannabis use accelerates cognitive decline or increases dementia risk in older adults. Surprisingly, baseline testing revealed cannabis users performed slightly better on numeric memory and fluid intelligence tasks, though these advantages didn't persist over time. Critically, longitudinal tracking showed no difference in the rate of cognitive change between users and non-users, while veterans with diagnosed cannabis use disorder showed no elevated dementia risk over follow-up periods.
The study employed Mendelian randomization to test for causal relationships, using genetic variants as natural experiments to eliminate confounding factors that plague observational cannabis research. This genetic analysis found no causal links between cannabis use and either cognitive performance or dementia risk, suggesting the observed associations reflect selection effects rather than drug effects.
These findings challenge assumptions about cannabis as a cognitive threat in aging populations, though important caveats remain. The research primarily captured occasional to moderate use patterns rather than heavy chronic consumption, and most participants likely used traditional THC-dominant products rather than modern high-potency formulations. While reassuring for typical older adult cannabis use, the results don't necessarily apply to intensive consumption patterns or contemporary ultra-high-THC products increasingly available in legal markets.